Anti-Corruption, Compliance Scrutiny Increase In Emerging Markets
This article was originally published in The Pink Sheet Daily
Executive Summary
In the next few years, the Department of Justice's enforcement focus will be the Foreign Corrupt Practices Act and its application to the pharmaceutical industry, DoJ official says.
You may also be interested in...
Overseas Contractor Bill Could Give Pharma Federal Contracting Headaches In U.S.
A U.S. House-passed bill that would bar firms from federal contracts if they violate the Foreign Corrupt Practices Act could put any violative pharma firms at risk of losing participation in drug benefit programs with the Department of Veterans Affairs, Medicaid and Medicare
Overseas Contractor Bill Could Give Pharma Federal Contracting Headaches In U.S.
House bill would bar firms in violation of the Foreign Corrupt Practices Act from federal contracts or grants.
Overseas Contractor Bill Could Give Pharma Federal Contracting Headaches In U.S.
House bill would bar firms in violation of the Foreign Corrupt Practices Act from federal contracts or grants.